We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+6.22%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.72B
AUM Growth
+$29.7M
Cap. Flow
+$160M
Cap. Flow %
5.89%
Top 10 Hldgs %
47.84%
Holding
110
New
9
Increased
24
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$71.7M
2
BHVN icon
Biohaven
BHVN
+$47.3M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$42.1M
4
SYY icon
Sysco
SYY
+$38.9M
5
AAPL icon
Apple
AAPL
+$34.8M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$48M
2
CI icon
Cigna
CI
+$45.6M
3
MCK icon
McKesson
MCK
+$30.5M
4
VZ icon
Verizon
VZ
+$23M
5
BCYC
Bicycle Therapeutics
BCYC
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 58.96%
2 Technology 10.09%
3 Communication Services 6.22%
4 Consumer Discretionary 5.49%
5 Financials 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
76
Natera
NTRA
$44.8B
$1.09M 0.04%
10,100
-14,500
-59% -$1.47M
MCK icon
77
McKesson
MCK
$103B
$1.07M 0.04%
1,830
-54,809
-97% -$30.5M
PTGX icon
78
Protagonist Therapeutics
PTGX
$9.42B
$1.06M 0.04%
30,500
– –
EW icon
79
Edwards Lifesciences
EW
$51.8B
$1.03M 0.04%
11,100
– –
HCA icon
80
HCA Healthcare
HCA
$89B
$1.02M 0.04%
3,190
– –
CVS icon
81
CVS Health
CVS
$122B
$1.01M 0.04%
17,170
– –
WAT icon
82
Waters Corp
WAT
$39.1B
$914K 0.03%
3,150
– –
ILMN icon
83
Illumina
ILMN
$28.8B
$911K 0.03%
8,730
-244
-3% -$27.4K
FIVE icon
84
Five Below
FIVE
$12.9B
$833K 0.03%
+7,645
New +$1.06M
HUM icon
85
Humana
HUM
$45.9B
$729K 0.03%
1,950
– –
DXCM icon
86
DexCom
DXCM
$31.5B
$667K 0.02%
5,880
– –
A icon
87
Agilent Technologies
A
$40.5B
$647K 0.02%
4,990
– –
VLTO icon
88
Veralto
VLTO
$24B
$523K 0.02%
5,475
– –
IONS icon
89
Ionis Pharmaceuticals
IONS
$9.18B
$515K 0.02%
10,800
– –
RMD icon
90
ResMed
RMD
$31.1B
$457K 0.02%
2,390
– –
MS icon
91
Morgan Stanley
MS
$338B
$448K 0.02%
4,611
-3,030
-40% -$288K
ZBH icon
92
Zimmer Biomet
ZBH
$18.4B
$354K 0.01%
3,260
– –
STE icon
93
Steris
STE
$22.8B
$336K 0.01%
1,530
– –
MREO
94
Mereo BioPharma
MREO
$48.5M
$270K 0.01%
75,000
-3,578,494
-98% -$11.6M
BAX icon
95
Baxter International
BAX
$14.1B
$267K 0.01%
7,970
– –
ALGN icon
96
Align Technology
ALGN
$12.1B
$266K 0.01%
1,100
– –
CRL icon
97
Charles River Laboratories
CRL
$12.7B
$209K 0.01%
1,010
– –
RVNC
98
DELISTED
Revance Therapeutics, Inc.
RVNC
$150K 0.01%
58,425
-1,541,575
-96% -$5.26M
ARGX icon
99
argenx
ARGX
$55.4B
– –
-121,900
Closed -$48M
BCYC
100
Bicycle Therapeutics
BCYC
$288M
– –
-914,476
Closed -$22.8M
1 2 3
4
5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Suvretta Capital Management held 110 positions worth $2.72B, up 1.1% from $2.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Suvretta Capital Management deployed $160M of net new capital in Q2 2024, opening 9 new positions and adding to 24 existing holdings. Its largest new stake was Sysco: 520,900 shares worth $37.2M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 58% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Cigna, an estimated $45.6M trimmed.

  • Suvretta Capital Management's largest Q2 2024 buy was Sysco: 520,900 shares worth $37.2M.
  • Suvretta Capital Management added most to UnitedHealth in Q2 2024, an estimated $71.7M increase.
  • Suvretta Capital Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $45.6M.
  • Suvretta Capital Management fully exited argenx in Q2 2024, selling an estimated $48M.
  • Suvretta Capital Management's ten largest holdings make up 48% of its $2.72B portfolio in Q2 2024.
  • Suvretta Capital Management opened 9 new positions and closed 12 in Q2 2024.
  • Suvretta Capital Management's portfolio value rose 1.1% quarter-over-quarter to $2.72B.

Based on Suvretta Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.